High Court overturns NHS decision not to fund 'highly effective' PrEP HIV drug

2 August 2016

The High Court in Britain has overturned a decision by NHS England to remove Pre-Exposure Prophylaxix (PrEP) for HIV from its commissioning process.

Following a legal challenge by the National AIDS Trust (NAT), High Court judge, Mr Justice Greening, said today that NHS England had "erred in deciding that it has no power or duty to commission the preventative drugs in issue.”

NHS England announced it will appeal the ruling and, in the meantime, put all provisional investment decisions for specialized services, including PrEP, on hold.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK